Allergen immunotherapy adverse events in adults with respiratory allergies‐data from ADER: An EAACI task force report
Nebenwirkungen der Allergenimmuntherapie bei Erwachsenen mit respiratorischen Allergien – Daten aus ADER: Bericht der EAACI Task Force
Allergy · 2025-03 · 80 (3) · 775-784
DOI: 10.1111/all.16286 ↗Auf einen Blick
In einem multizentrischen Register traten AIT-assoziierte Nebenwirkungen bei 7,4 % der Patient:innen auf; schwere Reaktionen waren selten und nur unter SCIT zu sehen.
Fragestellung
Wie häufig treten Nebenwirkungen unter Allergenimmuntherapie (AIT) bei Erwachsenen mit respiratorischen Allergien auf, und welche Risikofaktoren gibt es?
Methode
Prospektives, multizentrisches Register (ADER) zu realer AIT-Sicherheit bei Erwachsenen mit respiratorischen Allergien; Erfassung von AE mit MedDRA in 8 Ländern.
Ergebnisse
1545 Personen erhielten 1815 AIT-Zyklen (1060 SLIT; 755 SCIT). Es wurden 296 AE bei 115 Patient:innen (7,4 %) dokumentiert; 59 % traten in der Aufdosierung auf. Schwere Reaktionen: 0,2 %.
Schlussfolgerung der Autor:innen
Im klinischen Alltag treten AIT-assoziierte AE bei einer Minderheit der Patient:innen auf; schwere Reaktionen sind selten. Asthma und SCIT erhöhen das Risiko, modifizierte Allergene senken es.
Kernaussagen
- 296 AE bei 115 Patient:innen (7,4 %)
- Schwere Reaktionen selten: 0,2 %; nur unter SCIT
- Asthma und SCIT mit höherem AE-Risiko; Allergoide mit geringerem Risiko
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Allergy, online erschienen am 22.08.2024. Verfasst von Julijana Asllani und 19 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Medicine, Tirana, Albania. Hauptthemen laut MEDLINE: Desensitization, Immunologic, Respiratory Hypersensitivity. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: European Academy of Allergy and Clinical Immunology, Stallergenes.
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Registries can yield important insights on allergen immunotherapy (AIT) outcomes in daily clinical practice. However, systematic recordings of adverse events (AE) due to AIT in real‐life are lacking.
Methods
The Allergen Immunotherapy Adverse Events Registry (ADER) is a prospective, multicenter registry on real‐life AIT safety. Data on adults (>18 years old) with respiratory allergies receiving AIT with mites, pollens, epithelia, and/or molds were retrieved and analyzed from ADER. The frequency, characteristics and risk factors of AE were investigated. The MedDRA terminology was used to record AE.
Results
A total of 1545 individuals with a mean age of 33 ± 10 years receiving 1815 AIT courses ( n = 1060 sublingual (SLIT); n = 755 subcutaneous (SCIT)) in centers from eight countries were included. Patients had allergic rhinitis (65%) or, asthma only (3.7%) or rhinitis with asthma (31.2%). Grass was the most frequent specific sensitizer (60.7%), followed by mites (45.5%), birch pollen (20.6%), epithelia (16.1%), and molds (8%). There were 296 AE recorded in 115 patients (7.4%). A higher frequency of AE occurred during up‐dosing (59%) compared to maintenance. Severe reactions were rare (0.2%), all in the context of SCIT. After 6 weeks of maintenance only one moderate AE was recorded. The most frequently reported symptoms were from the respiratory system and the skin. Having asthma, doing SCIT, AIT with mugwort, cat, or birch were associated with higher risk for AE while the use of allergoids induced lower risk.
Conclusion
In real life clinical practice, AIT‐associated AE occur in a minority of patients, while severe reactions are rare. The presence of asthma and use of SCIT are risk factors, while the use of modified allergens lowers the risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Medicine, Tirana, Albania.
- Allergy and Asthma Medical Clinic, Tirana, Albania.
- Allergy Department 2nd Pediatric Clinic, University of Athens, Athens, Greece.
- Department of Allergy and Clinical Immunology, 424 General Military Training Hospital, Thessaloniki, Greece.
- University Hospital Center "Mother Teresa", Tirana, Albania.
- Ambulatory Polyclinic of Specialties, Tirana, Albania.
ORCID-Profile: Julijana Asllani, George Konstantinou, Mitja Kosnik, Nikolaos G Papadopoulos
Förderung
- European Academy of Allergy and Clinical Immunology
- Stallergenes
Zitieren
APA
Asllani, J., Mitsias, D., Konstantinou, G., Qirko, E., Hitaj, M., Musollari, S., Christoff, G., Novakova, S., Makris, M., Radulovic Pevec, M., Pevec, B., Muntean, A., Tomic-Spiric, V., Stosovic, R., Kosnik, M., Mungan, D., Popov, T. A., Calderon, M., Papadopoulos, N. G., & ADER Study Group (2025). Allergen immunotherapy adverse events in adults with respiratory allergies‐data from ADER: An EAACI task force report. Allergy, 80(3), 775-784. https://doi.org/10.1111/all.16286
Vancouver
Asllani J, Mitsias D, Konstantinou G, Qirko E, Hitaj M, Musollari S, et al. Allergen immunotherapy adverse events in adults with respiratory allergies‐data from ADER: An EAACI task force report. Allergy. 2025;80(3):775-784. doi:10.1111/all.16286
BibTeX
@article{Asllani2025,
author = {Asllani, Julijana and Mitsias, Dimitrios and Konstantinou, George and Qirko, Etleva and Hitaj, Mirela and Musollari, Sybi and Christoff, George and Novakova, Silviya and Makris, Michael and Radulovic Pevec, Mira and Pevec, Branko and Muntean, Adriana and Tomic-Spiric, Vesna and Stosovic, Rajica and Kosnik, Mitja and Mungan, Dilsad and Popov, Todor A and Calderon, Moises and Papadopoulos, Nikolaos G and ADER Study Group, ADER Study Group},
title = {Allergen immunotherapy adverse events in adults with respiratory allergies‐data from ADER: An EAACI task force report},
journal = {Allergy},
year = {2025},
volume = {80},
number = {3},
pages = {775--784},
doi = {10.1111/all.16286}
}
EUVIMED